2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2005020217v1 ASN.2005020217v2 17/2/475    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, S. X. Articles by Ma, J.-x. Search for Related Content PubMed PubMed Citation Articles by Zhang, S. X. Articles by Ma, J.-x. Related Collections Related Articles

Therapeutic Potential of Angiostatin in Diabetic Nephropathy

Department of Medicine Endocrinology, Department of Cell Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Address correspondence to: Dr. Jian-xing Ma, 941 Stanton L. Young Boulevard, BSEB 328B, Oklahoma City, OK 73104. Phone: 405-271-4372; Fax: 405-271-3973; jian-xing-ma{at}ouhsc.edu

Received for publication February 25, 2005. Accepted for publication November 25, 2005.

Angiostatin is a proteolytic fragment of plasminogen and a potent angiogenic inhibitor. Previous studies have shown that angiostatin inhibits retinal neovascularization and reduces retinal vascular permeability in diabetic retinopathy. Here, it is reported for the first time that angiostatin is also implicated in diabetic nephropathy (DN). Angiostatin levels are dramatically decreased in the kidney of streptozotocin-induced diabetic rats. Consistently, diabetic kidneys also showed decreased expression and proteolytic activities of matrix metalloproteinase-2, an enzyme that releases angiostatin from plasminogen. Adenovirus-mediated delivery of angiostatin significantly alleviated albuminuria and attenuated the glomerular hypertrophy in diabetic rats. Moreover, angiostatin treatment downregulated the expression of vascular endothelial growth factor and TGF-1, two major pathogenic factors of DN, in diabetic kidneys. In cultured human mesangial cells, angiostatin blocked the overexpression of vascular endothelial growth factor and TGF-1 that were induced by high glucose while increasing the levels of pigment epithelium–derived factor, an endogenous inhibitor of DN. Moreover, angiostatin effectively inhibited the high-glucose–and TGF-1–induced overproduction of proinflammatory factors and extracellular matrix proteins via blockade of the Smad signaling pathway. These findings suggest that the decrease of angiostatin levels in diabetic kidney may contribute to the pathologic changes such as inflammation and fibrosis in DN. Therefore, angiostatin has therapeutic potential in DN as a result of its anti-inflammatory and antifibrosis activities.

Related Articles

This Month’s Highlights
J. Am. Soc. Nephrol. 2006 17: 315-316. [Full Text] [PDF]

This article has been cited by other articles:

				T. Nasu, Y. Maeshima, M. Kinomura, K. Hirokoshi-Kawahara, K. Tanabe, H. Sugiyama, H. Sonoda, Y. Sato, and H. Makino Vasohibin-1, a Negative Feedback Regulator of Angiogenesis, Ameliorates Renal Alterations in a Mouse Model of Diabetic Nephropathy Diabetes, October 1, 2009; 58(10): 2365 - 2375. [Abstract] [Full Text] [PDF]

				T. Nakagawa, T. Kosugi, M. Haneda, C. J. Rivard, and D. A. Long Abnormal Angiogenesis in Diabetic Nephropathy Diabetes, July 1, 2009; 58(7): 1471 - 1478. [Full Text] [PDF]

				W. Mu, D. A. Long, X. Ouyang, A. Agarwal, P. E. Cruz, C. A. Roncal, T. Nakagawa, X. Yu, W. W. Hauswirth, and R. J. Johnson Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism Am J Physiol Renal Physiol, January 1, 2009; 296(1): F145 - F152. [Abstract] [Full Text] [PDF]

				X. Y. Shi, F. F. Hou, H. X. Niu, G. B. Wang, D. Xie, Z. J. Guo, Z. M. Zhou, F. Yang, J. W. Tian, and X. Zhang Advanced Oxidation Protein Products Promote Inflammation in Diabetic Kidney through Activation of Renal Nicotinamide Adenine Dinucleotide Phosphate Oxidase Endocrinology, April 1, 2008; 149(4): 1829 - 1839. [Abstract] [Full Text] [PDF]

				K. M. Thrailkill, R. C. Bunn, C. S. Moreau, G. E. Cockrell, P. M. Simpson, H. N. Coleman, J. P. Frindik, S. F. Kemp, and J. L. Fowlkes Matrix Metalloproteinase-2 Dysregulation in Type 1 Diabetes Diabetes Care, September 1, 2007; 30(9): 2321 - 2326. [Abstract] [Full Text] [PDF]

				A. A. Eddy and A. B. Fogo Plasminogen Activator Inhibitor-1 in Chronic Kidney Disease: Evidence and Mechanisms of Action J. Am. Soc. Nephrol., November 1, 2006; 17(11): 2999 - 3012. [Full Text] [PDF]

				R. Zent and A. Pozzi Antiangiogenic Therapy in Diabetic Nephropathy J. Am. Soc. Nephrol., February 1, 2006; 17(2): 325 - 327. [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673